Sign Out
NESP is indicated for the treatment of anaemia associated with chronic renal failure (CRF).
NESP is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.
NESP is also indicated for anaemia with myelodysplastic syndrome. The efficacy and safety of NESP have not been established in patients who are in the intermediate-2 or high risk categories under the International Prognostic Scoring System (IPSS). Patients indicated for NESP should be selected based on a full knowledge of the description in Pharmacology: Pharmacodynamics: CLINICAL TRIAL under Actions, including serum erythropoietin concentration in patients enrolled in clinical studies, as well as adequate understanding of the efficacy and safety of NESP and reference to the academic guidelines and other relevant updates.
